- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00461175
European Active Surveillance Study for Intrauterine Devices (EURAS-IUD)
Study Overview
Status
Conditions
Detailed Description
This is a large, multinational, prospective, controlled, long-term cohort study that follows a series of cohorts. The cohorts consist of new users of different groups of intrauterine devices (IUDs). Primarily, a non-interference approach - with exception of the standardized diagnostic workup to identify uterine perforations - will be used to provide standardized, comprehensive and reliable information on these IUDs under routine medical conditions.
The primary objective of the study is to assess the risks of intrauterine device (IUD) use in a study population that is representative for the actual users of the individual IUDs. The primary clinical outcome of interest is the uterine perforation rate. Secondary objectives are among others:
- the time intervals between IUD insertion and uterine perforation
- impact of post-partal IUD insertion on the uterine perforation rate
- proportion of uterine perforations associated with IUD insertion with serious clinical complications
- the incidences of medically relevant adverse events associated with IUP use
The combined cohort will include 60000 women recruited in six European countries. Enrollment should begin in November 2006 and end in 2012. Patients should undergo follow-up for at least 1 year.
Recruitment of the cohort members will be conducted via a network of approximately 2000 gynecologists.
Enrollment procedures should not interfere with the prescribing behavior of physicians or with the individual needs of the participating women. Influence on the preference for specific oral contraceptives is to be avoided but significant efforts are to be undertaken to ensure standardized, comprehensive and reliable documentation of all baseline characteristics and adverse events during the follow-up period.
The study participants are women aged 18 or older who have a new insertion of an IUD and who are willing to participate in this cohort study. There are no specific medical inclusion or exclusion criteria. However, women who are not cooperative may be excluded from study participation. Also women with a language barrier will not be eligible for study inclusion.
This study will maintain scientific independence and will be governed by an independent Advisory Council. The Center for Epidemiology and Health Research in Berlin, Germany and its research team will be accountable for the Advisory Council (AC) in all scientific matters. The members of the AC wil be international experts in relevant scientific fields (e. g. epidemiology, gynecology and cardiology).
The study started after all relevant legal and ethical requirements had been fulfilled. Information on the identity of the patients and treating physicians will be kept separated from the clinical information throughout the study. All relevant national data protection laws will be followed.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10115
- Center for Epidemiology and Health Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- women who have a new insertion of an IUD
- women who are willing to participate in this cohort study
Exclusion Criteria:
- women who are not cooperative
- women with a language barrier
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
1
Mirena®
|
2
Copper IUD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Uterine Perforation Rate
Time Frame: 12 months after insertion
|
Uterine perforation is a potentially serious complication of intrauterine device (IUD) use.
The absolute risk of uterine perforation associated with the LNG IUS in routine medical practice has not hitherto been well defined.
It is also unknown whether the perforation rate is higher with this IUD than with copper IUDs.
|
12 months after insertion
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Contraceptive Failure
Time Frame: Within 12 months
|
Intrauterine contraceptive methods have low Pearl Indices.
Nevertheless, there is a lack of comparative data between LNG IUS users and copper IUD users.
Women with unintended pregnancies were explicitly aked whether the pregnancy occured despite IUD use.
The 29 pregnancies that occured after unrecognized IUD expulsion were considered to have resulted from a failure of the contraceptive method and were therefore included in the analysis.
|
Within 12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Klaas Heinemann, MD, PhD, Center for Epidemiology and Health Research, Germany
Publications and helpful links
General Publications
- Heinemann K, Reed S, Moehner S, Minh TD. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices. Contraception. 2015 Apr;91(4):274-9. doi: 10.1016/j.contraception.2015.01.007. Epub 2015 Jan 16.
- Heinemann K, Reed S, Moehner S, Minh TD. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. Contraception. 2015 Apr;91(4):280-3. doi: 10.1016/j.contraception.2015.01.011. Epub 2015 Jan 16.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZEG2006_01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uterine Perforation
-
BayerCompletedIntrauterine DevicesUnited States
-
Kyungpook National University HospitalCompletedPerforation ColonKorea, Republic of
-
AdventHealthRecruitingFistula | GI Bleeding | Perforation Bowel | Perforated Bowel | Perforation Colon | Perforation DuodenalUnited States
-
University of British ColumbiaCompleted
-
Medical University of SilesiaCompletedCoronary Artery PerforationPoland
-
Affiliated Hospital to Academy of Military Medical...UnknownIntervention | Gastrointestinal PerforationChina
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingBlood Vessel PerforationChina
-
Hams Hamed AbdelrahmanCompleted
-
Zagazig UniversityCompletedIatrogenic Esophageal PerforationEgypt
-
West Virginia UniversityCompletedCesarean Delivery | Glove PerforationUnited States